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Alemtuzumab CARE-MS I 5-year
follow-up
Durable efficacy in the absence of continuous MS therapy
ABSTRACT
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients
with active relapsing-remitting MS (RRMS) (CARE-MS I; NCT00530348).
Methods: Alemtuzumab-treated patients received treatment courses at baseline and 12 months
later; after the core study, they could enter an extension (NCT00930553) with as-needed alem-
tuzumab retreatment for relapse or MRI activity. Assessments included annualized relapse rate
(ARR), 6-month confirmed disability worsening (CDW;$1-point Expanded Disability Status Scale
[EDSS] score increase [$1.5 if baseline EDSS 5 0]), 6-month confirmed disability improvement
(CDI; $1-point EDSS decrease [baseline score $2.0]), no evidence of disease activity (NEDA),
brain volume loss (BVL), and adverse events (AEs).
Results:Most alemtuzumab-treated patients (95.1%) completingCARE-MS I enrolled in the extension;
68.5% received no additional alemtuzumab treatment. ARR remained low in years 3, 4, and 5 (0.19,
0.14, and 0.15). Over years 0–5, 79.7% were free of 6-month CDW; 33.4% achieved 6-month CDI.
Most patients (61.7%, 60.2%, and 62.4%) had NEDA in years 3, 4, and 5. Median yearly BVL
improved over years 2–4, remaining low in year 5 (years 1–5: 20.59%, 20.25%, 20.19%,
20.15%, and 20.20%). Exposure-adjusted incidence rates of most AEs declined in the extension
relative to the core study. Thyroid disorder incidences peaked at year 3 and subsequently declined.
Conclusions: Based on these data, alemtuzumab provides durable efficacy through 5 years in the
absence of continuous treatment, with most patients not receiving additional courses.
ClinicalTrials.gov identifier: NCT00530348; NCT00930553.
Classification of evidence: This study provides Class III evidence that alemtuzumab durably im-
proves efficacy outcomes and slows BVL in patients with RRMS. Neurology® 2017;89:1107–1116
GLOSSARY
AE5 adverse event; ARR5 annualized relapse rate; BPF5 brain parenchymal fraction; BVL5 brain volume loss; CDI5 confirmed
disability improvement; CDW 5 confirmed disability worsening; DMT 5 disease-modifying therapy; EAIR 5 exposure-adjusted
incidence rate; EDSS 5 Expanded Disability Status Scale; IAR 5 infusion-associated reaction; ITP 5 immune thrombocytopenia;
NEDA 5 no evidence of disease activity; RRMS 5 relapsing-remitting MS; SC IFN-b-1a 5 subcutaneous interferon b-1a.
Alemtuzumab (LEMTRADA; Sanofi Genzyme, Cambridge, MA) is a humanized monoclonal
antibody that selectively targets CD52, an antigen highly expressed on T and B lymphocytes.1
Binding of alemtuzumab to CD52 results in depletion of circulating T and B cells,2,3 following
which a distinct pattern of T- and B-cell repopulation and a shift in cytokines toward a less
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inflammatory pattern occur. Both mecha-
nisms may be relevant to the durable efficacy
of this drug.4
Compared with the active treatment subcu-
taneous interferon b-1a (SC IFN-b-1a; Rebif;
EMD Serono Inc., Rockland, MA), alemtuzu-
mab significantly reduced the annualized
relapse rate (ARR) in patients with active
relapsing-remitting MS (RRMS) who either
were treatment-naive (phase 2 CAMMS223
study [NCT00050778]5 and phase 3 Com-
parison of Alemtuzumab and Rebif Efficacy
in Multiple Sclerosis [CARE-MS] I study
[NCT00530348])6 or had an inadequate
response ($1 relapse) to prior therapy (phase
3 CARE-MS II study [NCT00548405]).7 In
CAMMS223 and CARE-MS II, alemtuzu-
mab also increased proportions of patients
who were free of 6-month confirmed disability
worsening (CDW).5,7 Alemtuzumab increased
proportions with no evidence of disease activ-
ity (NEDA) in the 2-year phase 3 CARE-MS
studies6,7 and reduced brain volume loss
(BVL) in all 3 clinical trials, compared with
SC IFN-b-1a.5–7 The most common adverse
events (AEs) with alemtuzumab were
infusion-associated reactions (IARs); autoim-
mune AEs were also associated with treat-
ment.5–7 Based on the positive benefit-risk
profile demonstrated in these trials, alemtuzu-
mab is currently licensed in over 60 countries
worldwide for treatment of adults with
RRMS8,9 and is the only approved treatment
that does not require continuous dosing to
provide durable efficacy in patients with this
disease.
We report interim results through 3 years
of an extension study (NCT00930553) in pa-
tients who received alemtuzumab during the
core CARE-MS I trial, constituting a total
of 5 years of follow-up from CARE-MS I
enrollment.
METHODS Patients and procedures for CARE-MS I
core study. The study design for the 2-year CARE-MS I core
study has been published previously.6 Briefly, CARE-MS I was
a randomized, rater-blinded, active-controlled, head-to-head trial
of alemtuzumab compared with SC IFN-b-1a in patients who
were treatment-naive and had active RRMS ($2 relapses in the
previous 2 years and $1 relapse in the prior year).
Procedures for the extension study. This analysis reports
findings from alemtuzumab-treated patients who completed
CARE-MS I and continued into the extension, in which they
could receive additional alemtuzumab courses (each 12 mg/d IV
on 3 consecutive days) upon evidence of MS disease activity (and
$48 weeks since the prior course). Eligibility criteria for re-
treatment were$1 protocol-defined relapse or$2 new/enlarging
T2 hyperintense and/or gadolinium (Gd)-enhancing brain or
spinal cord lesions on MRI. Retreatment-disqualifying criteria
included, but were not limited to, pregnancy, diagnosis of
immune thrombocytopenia (ITP) or other immune cytopenia,
and history of malignancy (except basal cell carcinoma) or anti-
glomerular basement membrane disease. The decision on
whether to initiate retreatment in eligible patients was left to the
treating physician and patient, as was the decision to provide
another licensed disease-modifying therapy (DMT).
Efficacy assessments and endpoints. Relapse events required
objective signs on examination, lasting $48 hours, and were
confirmed by the investigator. The Expanded Disability Status
Scale (EDSS) was assessed quarterly and for evaluation of sus-
pected relapses by raters blinded to previous treatment assign-
ment and treatment history throughout the extension. Annual
MRI scans were assessed by blinded imaging specialists at Neu-
roRx Research (Montréal, Canada; for lesion-based analyses) and
the Cleveland Clinic MS MRI Analysis Center (Cleveland, OH;
for brain parenchymal fraction [BPF] analysis).
Clinical efficacy endpoints evaluated over years 0–5 included
the following: ARR; proportion of relapse-free patients; 6-month
CDW ($1.0-point EDSS score increase from core study baseline
[$1.5 if baseline EDSS score 5 0]; formerly termed sustained
accumulation of disability10); mean change from baseline EDSS
score; proportions of patients with EDSS scores that were
improved ($1.0-point decrease), worsened ($1.0-point
increase), or stable (#0.5-point change) compared with baseline;
and 3-, 6-, or 12-month confirmed disability improvement (CDI;
$1.0-point decrease from core study baseline EDSS score, in
patients with baseline EDSS scores $2.0).
MRI lesion outcomes examined over years 0–5 included pro-
portions of patients with Gd-enhancing, new/enlarging T2 hyper-
intense, and new nonenhancing T1 hypointense lesions. Median
percentage BVL from baseline and per year was calculated.
NEDA was evaluated annually and cumulatively (sustained
NEDA over years 3–5). NEDA was defined as no evidence of
clinical disease activity (absence of both relapses and 6-month
CDW) and no evidence of MRI lesion activity (absence of both
new Gd-enhancing and new/enlarging T2 hyperintense lesions).
Safety monitoring. Safety was evaluated by review of AEs, seri-
ous AEs, medical events of interest, and laboratory tests (includ-
ing thyroid function [at least quarterly], hematology [at least
monthly], serum creatinine [monthly], and urinalysis with
microscopy [monthly]). All safety monitoring procedures contin-
ued for 4 years after last alemtuzumab administration, or until
study end, whichever occurred later. IARs were defined as any
AE with onset during infusion or #24 hours after the end of
infusion.
Classification of evidence. This analysis evaluates the long-
term efficacy and safety of alemtuzumab and provides Class III
evidence that alemtuzumab improves ARR, MRI lesion out-
comes, and BVL over 5 years in treatment-naive patients with
active RRMS and that high proportions of patients achieve
NEDA. These effects were observed in the absence of continuous
treatment and with most (68.5%) patients receiving no alemtu-
zumab retreatment through 5 years.
Statistical analysis. Analyses were based on available data
(without imputation) on all alemtuzumab 12 mg patients with
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up to 5 years of follow-up from first dose in CARE-MS I, with an
interim cutoff date of October 4, 2014, in the extension.
ARR was estimated using negative binomial regression with
robust variance estimation and covariate adjustment for the geo-
graphic region. Proportions of patients with 6-month CDW or
3-, 6-, or 12-month CDI were estimated with the Kaplan-Meier
method. Percentage of patients with improvement, stability, or
worsening from the baseline EDSS score was reported.
Safety data were reported as incidences (percentage of patients
with $1 event) and exposure-adjusted incidence rates (EAIRs)
per 100 patient-years ([number of patients with specific event
divided by total annual exposure-time among patients at risk of
Figure 1 Patient disposition
Disposition schematic includes patient participation from the core CARE-MS I study through the long-term extension study. DMTs include fingolimod (n5 1),
glatiramer acetate (n 5 2), interferon b-1a (n 5 2), interferon b-1b (n 5 3), and natalizumab (n 5 1). *The death that occurred in the core study was deemed
not related to treatment. CARE-MS 5 Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; DMT 5 disease-modifying therapy.
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Figure 2 Clinical efficacy and disease activity outcomes over 5 years in alemtuzumab patients
(A) ARR over 5 years in alemtuzumab patients. Results are shown for all patients who received alemtuzumab 12 mg in the core CARE-MS I study and then
enrolled in the extension. A post hoc analysis revealed no statistically significant difference between ARRs in individual extension years (years 3, 4, and 5)
and the ARR in years 0–2. (B) EDSS score change in alemtuzumab patients over 5 years. Proportion of patients with improved ($1.0-point decrease), stable
(#0.5-point change), or worsened ($1.0-point increase) EDSS scores at year 5 compared with core study baseline. EDSS score changes are shown for all
patients who received alemtuzumab 12 mg in the core study and enrolled in the extension. (C) Proportion of alemtuzumab patients with 3-, 6-, or 12-month
CDI over 5 years. Kaplan-Meier analysis of time to 3-, 6-, or 12-month CDI is shown for all patients who received alemtuzumab 12mg in the core CARE-MS I
study and then enrolled in the extension. (D) Proportion of alemtuzumab patients with NEDA over 5 years. Results are shown for all patients who received
alemtuzumab 12 mg in the core CARE-MS I study and then enrolled in the extension. *Baseline percentage of patients Gd-enhancing lesion-free: 54%.
ARR 5 annualized relapse rate; CARE-MS 5 Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CDI5 confirmed disability improvement;
CDW 5 confirmed disability worsening; EDSS 5 Expanded Disability Status Scale; Gd 5 gadolinium; NEDA 5 no evidence of disease activity.
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initial occurrence of the event] 3 100) in the reported time
cohorts.11 Autoimmune AEs were reported using time of first
AE occurrence over total follow-up time (0–5 years).
Standard protocol approvals, registrations, and patient
consents. This trial is registered with ClinicalTrials.gov
(NCT00530348; NCT00930553). All procedures were
approved by local institutional ethics review boards of partici-
pating sites. Patients provided written informed consent.
RESULTS Patients. Of the 367 alemtuzumab pa-
tients completing CARE-MS I, 349 (95.1%)
entered the extension study; of these, 335 (96.0%)
remained on study through Month 60 (year 5;
figure 1).
In the core study, alemtuzumab patients received
12 mg on 5 consecutive days at baseline and 3 consec-
utive days 12 months later. In the extension study,
239 (68.5%) alemtuzumab patients received no alem-
tuzumab retreatment; 341 (97.7%) received no other
DMT; and 235 (67.3%) received neither alemtuzu-
mab retreatment nor other DMT. Of the 110 pa-
tients who received alemtuzumab retreatment (table
e-1 at Neurology.org), 77 (70.0%), 28 (25.5%),
and 5 (4.5%) received a total of 1, 2, and 3 alemtu-
zumab retreatment courses, respectively, over years
3–5. The most common reason given by investigators
for alemtuzumab retreatment was relapse (51.0% of
retreatment courses for which a reason was provided),
followed by MRI lesion activity (25.9%), and com-
bined relapse and MRI lesion activity (23.1%).
Efficacy. ARR remained low during the extension,
similar to that in the core study (figure 2A).6 Mean
EDSS score changes from core study baseline were
improvements (i.e., reductions) at year 2 (20.16), at
year 3 (20.10), at year 4 (20.09), and 0.00 at year 5.
Compared with core study baseline, 60.0% of pa-
tients at year 5 showed stable EDSS scores; 22.2%
showed improved scores ($1-point decrease) and
17.8% showed worsened scores ($1-point increase;
figure 2B). Over 5 years, 79.7% (95% CI 75.1%–
83.6%) of patients were free of 6-month CDW, and
33.4% (95% CI 27.5%–40.1%) achieved 6-month
CDI (figure 2C).
Most alemtuzumab-treated patients were free of
clinical disease activity or MRI lesion activity during
each extension year and most also attained NEDA
(figure 2D). Cumulatively over years 3–5, most pa-
tients showed no clinical (65.3%) or MRI lesion
(53.8%) activity, and 39.5% attained sustained
NEDA. During each extension year, most patients
were free of new T1 hypointense lesions (year 3,
89.2%; year 4, 85.4%; year 5, 85.4%).
The rate of yearly BVL continued to decrease after
the core study and seemed to stabilize in years 3, 4,
and 5 (figure 3). Median cumulative BPF change
from baseline to year 5 was –1.352%.
Further analyses evaluated outcomes among the
175 patients who achieved NEDA in year 2 and
received no alemtuzumab retreatment after the initial
2 courses and no other DMT (figure e-1A). Most pa-
tients achieved NEDA in each year of the extension
and 60.8% attained NEDA through years 2–5, re-
flecting high proportions of relapse-free, 6-month
CDW-free and new Gd-enhancing and T2 hyperin-
tense lesion-free patients (figure e-1B); this cohort
with sustained NEDA demonstrated slowing of
median annual BVL (figure e-2).
Safety. AEs occurring in alemtuzumab-treated patients
throughout the core and extension studies (up to the
cutoff date; 1767.7 patient-years over 5-year follow-
up) are summarized in tables 1 and 2 and table e-2.
The EAIR for overall AEs was lower in the extension
(years 3–5, 133.6) than in the core study (years 0–2,
705.2). Serious AE incidence remained low over
5 years. Most AEs (96.9%) in years 3–5 were mild to
moderate in severity. No AEs led to study withdrawal
in the extension. One death, reported previously,
occurred during the extension (in year 3), due to sepsis
that developed in the setting of pancytopenia and was
judged by the investigator to be treatment-related.6
Figure 3 Brain volume loss over 5 years in alemtuzumab patients
Median yearly percentage change in BPF is shown for all patients who received alemtuzumab
12 mg in the core CARE-MS I study and then enrolled in the extension. BPF 5 brain paren-
chymal fraction; CARE-MS 5 Comparison of Alemtuzumab and Rebif Efficacy in Multiple
Sclerosis.
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IAR incidences in patients receiving alemtuzumab
retreatment in the extension were lower than in the
core study (table 2). No serious IARs occurred during
the extension (courses 3, 4, or 5). Similar to the core
study,6 the most frequently reported IARs with alem-
tuzumab retreatment in the extension were headache,
pyrexia, and rash. When IARs were removed from the
count of any AEs overall, the EAIR remained lower in
the extension (129.2) compared with that in the core
study (174.8).
Overall incidences and EAIRs of infections over
years 3–5 were lower than during the core study
(table 1 and table e-2); 99.2% were mild to moderate
in severity. Infection incidence did not increase with
successive alemtuzumab courses (table e-3). As in the
core study, the most common infection events in the
extension were nasopharyngitis, urinary tract infec-
tion, upper respiratory tract infection, and herpetic
infections (predominantly mucocutaneous). The
incidence of serious infections remained low; the
most frequent was herpes zoster, with a total of 5
cases occurring over years 0–5 (4 were during the
extension).
The most common autoimmune AEs occurring
during the extension were thyroid AEs, which
peaked in year 3 and subsequently declined in years
4 and 5 (years 1–5 incidences: 6.4%, 9.6%, 15.3%,
7.6%, and 3.5%; incidence over 5 years was 40.7%).
Of the thyroid AEs reported in years 3–5, 62.1%
were moderate and 27.1% were mild in severity.
Similar incidences were observed over time for the
broader category of thyroid disorders (table 1 and
table e-2), which include abnormal thyroid function
tests (thyroid-stimulating hormone, free triiodothy-
ronine [T3], free thyroxine [T4]) in addition to
investigator-reported thyroid AEs; incidence over 5
years was 45.5%. Few serious thyroid AEs were re-
ported. As in the core study, the most frequently
reported thyroid disorders in the extension were lab-
oratory abnormalities, and clinical hyperthyroidism
and hypothyroidism. Thirteen thyroidectomies were
reported over years 0–5; most patients undergoing
Table 1 AEs through year 5 of the extension in patients treated with alemtuzumab 12 mg
Incidence, core and extension studies (5 y), n (%)a
EAIR per 100 patient-years
(no. of events)b
Core
study
(2 y)
Extension
study
(3 y)
Core and
extension
studies
(5 y)
Year 1
(n 5 376)
Year 2
(n 5 376)
Year 3
(n 5 360c)
Year 4
(n 5 344)
Year 5
(n 5 340)
Years 0–2
(n 5 376)
Years 3–5
(n 5 360)
Years 0–5
(n 5 376)
Any AE 353 (93.9) 316 (84.0) 273 (75.8) 253 (73.5) 233 (68.5) 705.2 133.6 512.5
Any AE excluding IARsd 297 (79.0) 282 (75.0) 270 (75.0) 251 (73.0) 231 (67.9) 174.8 129.2 146.6
AE leading to study drug discontinuation 4 (1.1) 1 (0.3) 0 0 0 0.7 (5) 0 0.3 (5)
Any serious AE 45 (12.0) 29 (7.7) 36 (10.0) 29 (8.4) 17 (5.0) 10.1 7.0 7.8
Any serious AE excluding IARs 36 (9.6) 27 (7.2) 36 (10.0) 29 (8.4) 17 (5.0) 8.3 7.0 6.9
Death 0 1 (0.3) 1 (0.3) 0 0 0.1 (1) 0.1 (1) 0.1 (2)
Any infection event 211 (56.1) 178 (47.3) 166 (46.1) 141 (41.0) 136 (40.0) 67.8 45.2 49.3
Serious infections 6 (1.6) 1 (0.3) 6 (1.7) 2 (0.6) 2 (0.6) 0.9 (7) 0.8 (8) 0.9 (15)
Any thyroid disorder e,f 31 (8.2) 48 (12.8) 60 (16.7) 22 (6.4) 10 (2.9) 11.5 15.1 13.2
Serious thyroid AEs 2 (0.5) 2 (0.5) 12 (3.3) 1 (0.3) 3 (0.9) 0.5 (4) 1.6 1.2
ITPe 1 (0.3) 2 (0.5) 0 1 (0.3) 0 0.4 (3) 0.1 (1) 0.2 (4)
Nephropathye 0 0 1 (0.3) 0 0 0 0.1 (1) 0.1 (1)
Malignant disease 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3) 2 (0.6) 0.3 (2) 0.4 (4) 0.3 (6)
Abbreviations: AE 5 adverse event; EAIR 5 exposure-adjusted incidence rate; IAR 5 infusion-associated reaction; ITP 5 immune thrombocytopenia.
a Percentage is based on the number of patients having an AE in the reported year divided by the total number of patients followed up in that year.
b (Number of patients with a specific event divided by the total exposure-time among patients at risk of an initial occurrence of the event) 3 100. Events
occurring in ,1 per 100 patient-years include the number of events in parentheses.
c In addition to the patients enrolled in the extension study, the safety analyses included a small number of core study patients (n 5 11), who did not enter
the extension but were evaluated for AEs temporarily after the initial 2-year period.
dAll patients with any AE, excluding those patients whose only AEs were IARs. IARs were any AE that occurred during the infusion or within 24 hours after
the end of the infusion.
e Includes first event by year of occurrence.
f Defined as any thyroid AE or abnormal thyroid-stimulating hormone level, with simultaneously abnormal free triiodothyronine (T3) or free thyroxine (T4) on
the same visit.
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thyroidectomies were subsequently maintained on
thyroxine.
One new case of ITP was reported during the
extension (year 4). The patient had a postalemtuzu-
mab history of autoimmune hemolytic anemia that
had resolved with treatment 2 years before ITP onset.
At last follow-up, the patient was receiving oral pred-
nisone for ITP, which was considered resolved several
months after the initial event.
There was a single case of nephropathy reported in
year 3 (4 months after the third alemtuzumab
course). The patient presented with hematuria and
proteinuria. Serum creatinine levels remained normal,
but there was weak seropositivity for antiglomerular
basement membrane autoantibodies. A renal biopsy
revealed focal global glomerulosclerosis and changes
indicative of membranous nephropathy, but no evi-
dence of antiglomerular basement membrane disease.
By 39 months after the initial event, following treat-
ment with plasmapheresis, glucocorticosteroids, and
cyclophosphamide, serum creatinine levels remained
normal, proteinuria was absent, and the patient did
not develop kidney failure.
Over 5 years, a total of 6 malignancies were re-
ported in alemtuzumab-treated patients (EAIR of
0.3 per 100 patient-years). Two malignancies
occurred in the core study (both papillary thyroid car-
cinomas), and 4 malignancies were reported in years
3–5 (n 5 1 each for breast cancer, keratoacanthoma,
non–small-cell lung cancer, and micropapillary thy-
roid carcinoma).
DISCUSSION Damage to neurons and axons starts
in the earliest stages of MS and is clinically relevant,
as it may foreshadow evolution of neurologic disabil-
ity.12,13 CNS tissue destruction can be quantified by
MRI as cerebral atrophy, which is accelerated in pa-
tients with MS compared with healthy individuals.14
Thus, to prevent accumulation of permanent neuro-
logic damage, early intervention in MS is important
and warranted.15 However, experts have not reached
consensus regarding what constitutes appropriate
early-stage treatment for patients with adverse prog-
nostic factors (e.g., an early disease course that in-
cludes frequent relapses, MRI lesion volume change,
or brain atrophy).16–18 Some physicians may initially
Table 2 IAR events through year 5 in patients treated with alemtuzumab 12 mg
IARsb by course
Incidence, n (%)a
Core study Extension study
Patients
receiving
initial 2
courses
Patients
receiving
retreatment
Course 1
(n 5 376)
Course 2
(n 5 370)
Course 3
(n 5 110)
Course 4
(n 5 33)
Course 5
(n 5 5)
Courses 1–2
(n 5 376)
Courses 3–5
(n 5 110)
Any IAR 323 (85.9) 243 (65.7) 72 (65.5) 18 (54.5) 2 (40.0) 338 (89.9) 73 (66.4)
IAR events affecting >10% of
patients over courses 1–5
Rashc 154 (41.0) 65 (17.6) 13 (11.8) 5 (15.2) 1 (20.0) 165 (43.9) 15 (13.6)
Headache 133 (35.4) 103 (27.8) 31 (28.2) 6 (18.2) 0 160 (42.6) 33 (30.0)
Pyrexia 81 (21.5) 63 (17.0) 19 (17.3) 3 (9.1) 1 (20.0) 125 (33.2) 22 (20.0)
Nausea 40 (10.6) 21 (5.7) 9 (8.2) 4 (12.1) 0 52 (13.8) 13 (11.8)
Flushing 30 (8.0) 20 (5.4) 4 (3.6) 3 (9.1) 0 43 (11.4) 6 (5.5)
Urticaria 38 (10.1) 11 (3.0) 3 (2.7) 0 0 43 (11.4) 3 (2.7)
Pruritusd 30 (8.0) 10 (2.7) 1 (0.9) 5 (15.2) 0 39 (10.4) 6 (5.5)
Chills 28 (7.4) 14 (3.8) 5 (4.5) 0 0 38 (10.1) 5 (4.5)
Insomnia 23 (6.1) 18 (4.9) 7 (6.4) 1 (3.0) 0 37 (9.8) 8 (7.3)
Serious IARse 10 (2.7) 2 (0.5) 0 0 0 12 (3.2) 0
Abbreviation: IAR 5 infusion-associated reaction.
a Percentage is based on the number of patients having an IAR in the reported course divided by the total number of patients followed up for that course.
b IARs were any adverse event that occurred during the infusion or within 24 hours after the end of the infusion.
c Rash includes the preferred terms rash and rash generalized.
d Pruritus includes the preferred terms pruritus and pruritus generalized.
e The following serious IARs occurred in 2 patients each: atrial fibrillation (course 1), incorrect dose administered (course 1), and hypotension (course 1). The
following serious IARs occurred in 1 patient each: anaphylactic shock (course 1), angioedema (course 1), bradycardia (course 1), brain stem syndrome
(course 2), chest discomfort (course 1), headache (course 2), migraine (course 1), myalgia (course 2), nausea (course 2), pleurisy (course 1), pyrexia (course
2), sinus bradycardia (course 1), sinus tachycardia (course 1), tachycardia (course 2), throat tightness (course 1), and urticaria (course 1). No serious IARs
occurred in courses 3, 4, or 5.
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prescribe a low- to moderate-efficacy therapy and may
switch to high-efficacy therapy upon evidence of an
inadequate response (e.g., disease activity while on
therapy), whereas others favor an individualized
approach involving higher-efficacy agents from the
outset.19 CARE-MS I compared these approaches in
patients with active RRMS and found greater im-
provements in relapse and MRI outcomes, as well as
higher attainment of NEDA, in patients who received
alemtuzumab compared with SC IFN-b-1a.6
We show that these findings were extended in the
CARE-MS I alemtuzumab treatment arm, with dura-
ble improvements in key efficacy outcomes over
5 years, including low ARR and most patients having
stable/improved EDSS scores and freedom from
6-month CDW. Additionally, more than one-third
achieved 6-month CDI. This endpoint captures dura-
ble and clinically meaningful EDSS score changes in
individual patients with preexisting neurologic im-
pairments; improving disability in those patients
may lead to better long-term prognosis.20 Our study
reports durable improvement in disability by using
this stringent outcome measure over several years in
a large MS patient cohort. Additionally, during each
of years 3, 4, and 5, a consistent proportion of about
60% of patients achieved NEDA; when the rigorous
goal of sustained NEDA was assessed cumulatively
over years 3–5, 40% of patients satisfied this
endpoint. These effects were observed in the absence
of continuous treatment and despite no retreatment
in the majority of patients. Similar durable efficacy
improvements were also shown for patients with
active RRMS who had an inadequate response to
prior therapy.21
Previous studies have shown the predictive value
of brain atrophy on disability outcomes in the early
years after MS diagnosis.18 Treatment effects on brain
atrophy and lesion activity correlate with treatment
effects on disability and cognitive dysfunction for
some therapies.14,18,22–24 No current therapies are
known to reverse CNS damage. Alemtuzumab
slowed the annual rate of BVL over years 3–5. More-
over, alemtuzumab-treated patients showed less
cumulative atrophy after 5 years (reported in this
study) compared with that observed in patients who
had received SC IFN-b-1a in the core study and then
switched to alemtuzumab in the extension (median
BPF changes of21.352% vs21.646%, respectively;
p 5 0.0086),25 illustrating the long-term benefits of
early treatment with alemtuzumab.
Durable efficacy with alemtuzumab over the
3-year extension follow-upwas accompanied by a safety
profile consistent with that observed in the core study.
Overall AEs, including IARs and infections,
decreased over time relative to the core study, with
a low but persistent risk of herpes zoster reactivation.
Autoimmune thyroid AEs peaked at year 3 and
declined thereafter. The rate of malignancies did
not increase from the core study through the exten-
sion. Two cases of papillary thyroid carcinomas were
seen in the core study; only 1 new micropapillary thy-
roid carcinoma event was reported over the next
3 years. The apparent rate of thyroid malignancies
observed with alemtuzumab in the MS clinical trial
program may have been inflated by ascertainment
bias owing to a more frequent occurrence of nonma-
lignant thyroid disorders and their diagnostic
workup26 with alemtuzumab than with SC IFN-
b-1a. These observations relating to safety with alem-
tuzumab are in contrast to AE rates that have been
observed with long-term use of chronically dosed
DMTs, in which the known risks associated with
a particular agent may increase or remain constant
with continued exposure to drug.27–29 With alemtu-
zumab, because of its unique dosing schedule and
lack of continuous treatment, most risks decrease over
time. Procedures for regular monitoring and manage-
ment help to maximize the risk-benefit profile.
As is often cited as a limitation of extension stud-
ies, the active comparator design of the pivotal
CARE-MS trials6,7 was not continued in the exten-
sion period, thus precluding long-term direct com-
parison with another treatment. Nonetheless, these
5-year data from patients who were treatment-naive
and had a mean disease duration of 2 years upon entry
into CARE-MS I demonstrate durable, long-term
therapeutic effects on clinical disease activity meas-
ures, as well as on more objective measures such as
MRI lesion activity and brain atrophy. The robust-
ness of our results is supported by the high patient
enrollment rate coupled with the unusually high
retention rate (.95% through year 5). Notably, the
latter suggests that the favorable outcomes in our
study cannot reflect selective dropout of poor res-
ponders. The continued use of blinded raters also
helped ensure unbiased efficacy analyses.
The sustained responses to alemtuzumab observed
over 5 years in our study highlight the value of a dura-
ble, high-efficacy therapy in the absence of continu-
ous treatment in patients who may be at high risk
of MS-related disability worsening and BVL. Risks
associated with the therapy are anticipated in advance
of treatment, and monitoring procedures
for minimizing adverse effects are implemented to
maintain a positive risk-benefit profile.
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